Risk of hospitalisation and death in children with SARS-CoV-2 delta (B.1.612.2) infection

Research output: Contribution to journalLetterpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)e16-e17
JournalThe Lancet Child and Adolescent Health
Issue number5
Early online date29 Mar 2022
Publication statusPublished - May 2022

Bibliographical note

Funding Information: All authors declare no competing interests. SNL conceived the study and assisted with writing the Correspondence. ST analysed data and wrote the first draft of the Correspondence. FA collected data. KH validated data. All authors contributed to interpretation of the results and discussion of the findings. This study did not receive any funding. We thank the national collaborative effort undertaken by the institutions participating in the COVID-19 Genomics UK (COG-UK) consortium that enables this national public health response. COG-UK is supported by funding from the Medical Research Council part of UK Research & Innovation, the National Institute of Health Research, and Genome Research Limited, operating as the Wellcome Sanger Institute. The UK Health Security Agency has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to process patient confidential information for national surveillance of communicable diseases and as such, individual patient consent is not required to access records.

Open Access: Free to read, but no Open Access licence.

Publisher Copyright: Crown Copyright © 2022 Published by Elsevier Ltd. All rights reserved.

Citation: Simon Thelwall, Felicity Aiano, Katie Harman, Gavin Dabrera, Shamez N Ladhani, Risk of hospitalisation and death in children with SARS-CoV-2 delta (B.1.612.2) infection, The Lancet Child & Adolescent Health, Volume 6, Issue 5, 2022, Pages e16-e17, ISSN 2352-4642,

DOI: https://doi.org/10.1016/S2352-4642(22)00096-7

Cite this